Outputs (81)

HOX genes in normal, engineered and malignant hematopoiesis (2018)
Journal Article
Collins, E. M., & Thompson, A. (2018). HOX genes in normal, engineered and malignant hematopoiesis. International Journal of Developmental Biology, 62(11-12), 847-856. https://doi.org/10.1387/ijdb.180206at

© 2018 UPV/EHU Press. Advanced technologies and models systems are improving our understanding of developmental processes. A primary example, hematopoiesis, classically represented by a hierarchical tree with a stem cell at the apex and more lineage... Read More about HOX genes in normal, engineered and malignant hematopoiesis.

Mirtazapine for chronic breathlessness? A review of mechanistic insights and therapeutic potential (2018)
Journal Article
Lovell, N., Wilcock, A., Bajwah, S., Etkind, S., Jolley, C., Maddocks, M., & Higginson, I. (2019). Mirtazapine for chronic breathlessness? A review of mechanistic insights and therapeutic potential. Expert Review of Respiratory Medicine, 13(2), 173-180. https://doi.org/10.1080/17476348.2019.1563486

Introduction: Chronic breathlessness is a common and distressing symptom of advanced disease with few effective treatments. Central nervous system mechanisms are important in respiratory sensation and control. Consequently, drugs which may modify pro... Read More about Mirtazapine for chronic breathlessness? A review of mechanistic insights and therapeutic potential.

Upper GI biopsies for adenocarcinoma: how many biopsies should endoscopists take? (2018)
Journal Article
Kaye, P., Lindsay, D., Madhusudan, S., Vohra, R., Catton, J., Platt, C., & Ragunath, K. (2019). Upper GI biopsies for adenocarcinoma: how many biopsies should endoscopists take?. Histopathology, 74(6), 959-963. https://doi.org/10.1111/his.13816

Aims: There is evidence that 4 or 5 gastric cancer biopsies are required for accurate HER2 interpretation. However, the number of biopsies that need to be taken to reach this number of viable cancer biopsies is without evidence. This study aimed to a... Read More about Upper GI biopsies for adenocarcinoma: how many biopsies should endoscopists take?.

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells (2018)
Journal Article
Grundy, M., Balakrishnan, S., Fox, M., Seedhouse, C., & Russell, N. (2018). Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells. Oncotarget, 9, Article 102. https://doi.org/10.18632/oncotarget.26540

Acute myeloid leukaemia (AML) cells often up-regulate pro-survival members of the BCL-2 protein family, such as BCL-2 and MCL-1, to avoid apoptosis. Venetoclax (ABT-199) targets BCL-2 and has shown promising efficacy in AML but over-expression of MCL... Read More about Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4 (2018)
Journal Article
Tzelepis, K., De Braekeleer, E., Aspris, D., Barbieri, I., Vijayabaskar, M. S., Liu, W.-H., Gozdecka, M., Metzakopian, E., Toop, H. D., Dudek, M., Robson, S. C., Hermida-Prado, F., Yang, Y. H., Babaei-Jadidi, R., Garyfallos, D. A., Ponstingl, H., Dias, J. M. L., Gallipoli, P., Seiler, M., Buonamici, S., …Vassiliou, G. S. (2018). SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Nature Communications, 9(1), Article 5378. https://doi.org/10.1038/s41467-018-07620-0

We recently identified the splicing kinase gene SRPK1 as a genetic vulnerability of acute myeloid leukemia (AML). Here, we show that genetic or pharmacological inhibition of SRPK1 leads to cell cycle arrest, leukemic cell differentiation and prolonge... Read More about SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4.

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer (2018)
Journal Article
Joseph, C., Arshad, M., Kurozomi, S., Althobiti, M., Miligy, I. M., Al-Izzi, S., Toss, M. S., Goh, F. Q., Johnston, S. J., Martin, S. G., Ellis, I. O., Mongan, N. P., Green, A. R., & Rakha, E. A. (2019). Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 174(2), 387-399. https://doi.org/10.1007/s10549-018-05085-9

Purpose
CD133/ prominin 1 is a cancer stem cell marker associated with cancer progression and patient outcome in a variety of solid tumours, but its role in invasive breast cancer (BC) remains obscure. The current study aims to assess the prognostic... Read More about Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis (2018)
Journal Article
Martínez-Calle, N., Hartley, S., Ahearne, M., Kasenda, B., Beech, A., Knight, H., Balotis, C., Kennedy, B., Wagner, S., Dyer, M. J. S., Smith, D., McMillan, A. K., Miall, F., Bishton, M., & Fox, C. P. (2019). Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. British Journal of Haematology, 184(6), 957-968. https://doi.org/10.1111/bjh.15722

Delayed lymphocyte and T-cell immune reconstitution following bendamustine-rituximab (BR) for indolent non-Hodgkin lymphoma (iNHL) has been described, but no information is available for chronic lymphocytic leukaemia (CLL). We present a population-ba... Read More about Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.

TGFβ1-induced cell motility but not cell proliferation is mediated through Cten in colorectal cancer (2018)
Journal Article
Asiri, A., Raposo, T. P., Alfahed, A., & Ilyas, M. (2018). TGFβ1-induced cell motility but not cell proliferation is mediated through Cten in colorectal cancer. International Journal of Experimental Pathology, 99(6), 323-330. https://doi.org/10.1111/iep.12300

Cten (C-terminal tensin-like) is a member of the tensin protein family found in complex with integrins at focal adhesions. It promotes epithelial‐mesenchymal transition (EMT) and cell motility. The precise mechanisms regulating Cten are unknown, alth... Read More about TGFβ1-induced cell motility but not cell proliferation is mediated through Cten in colorectal cancer.

Connexin 43 is an independent predictor of patient outcome in breast cancer patients (2018)
Journal Article
Chasampalioti, M., Green, A. R., Ellis, I. O., Rakha, E. A., Jackson, A. M., Spendlove, I., & Ramage, J. M. (2019). Connexin 43 is an independent predictor of patient outcome in breast cancer patients. Breast Cancer Research and Treatment, 174(1), 93-102. https://doi.org/10.1007/s10549-018-5063-9

Purpose

Gap junctions are specialized membrane structures that form channels between adjacent cells allowing cell communication. Gap junctions and specifically Connexin 43 (Cx43) are down-regulated in cancer; however, there are contrasting reports... Read More about Connexin 43 is an independent predictor of patient outcome in breast cancer patients.

Glutamate dehydrogenase (GLUD1) expression in breast cancer (2018)
Journal Article
Craze, M. L., El-Ansari, R., Aleskandarany, M. A., Cheng, K. W., Al-Farsi, L., Masisi, B., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2019). Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Research and Treatment, 174(1), 79–91. https://doi.org/10.1007/s10549-018-5060-z

Dysregulated cellular metabolism is regarded as one of the hallmarks of cancer with some tumours utilising the glutamine metabolism pathway for their sustained proliferation and survival. Glutamate dehydrogenase (GLUD1) is a key enzyme in glutaminoly... Read More about Glutamate dehydrogenase (GLUD1) expression in breast cancer.